Purchase Order 75N91024P00642

The National Cancer Institute (NCI), a component of the National Institutes of Health under the Department of Health and Human Services, awarded a firm fixed-price purchase order to Becton, Dickinson and Company (BD), through its BD Biosciences division, for preventive maintenance services on a government-owned BD LSRFortessa Flow Cytometer. This contract, valued at $144,941.40, represents the exercise of Option Period One under the original maintenance agreement and extends through August 31, 2029. The work will be performed at NCI's main campus in Bethesda, Maryland, and will be delivered by factory-trained and authorized BD technicians responding within 48 hours to minimize instrument downtime. The procurement was conducted on a sole-source basis under FAR Part 12 commercial item procedures, as BD is recognized as both the original equipment manufacturer and the only authorized service provider capable of delivering the required specialized maintenance services.

This contract supports NCI's critical research infrastructure by ensuring the continued operational capability of advanced flow cytometry equipment essential to cancer research and related biomedical investigations. Becton, Dickinson and Company, a global medical technology manufacturer with extensive federal contract experience across multiple agencies including the Department of Veterans Affairs, Centers for Disease Control and Prevention, and other NIH institutes, maintains a proven track record in providing specialized flow cytometry systems and maintenance services to government healthcare and research institutions. No small business set-aside designation was applied to this procurement, reflecting BD's established position as a large, for-profit manufacturer in the federal marketplace.